Mice lacking the serotonin 5-HT2B receptor as an animal model of resistance to selective serotonin reuptake inhibitors antidepressants

European Neuropsychopharmacology

Volumn 26, Issue 2, 2016, Pages 265-279

  Diaz, Silvina Laura ^a,b,c,d   Narboux Nême, Nicolas ^a,b,c   Boutourlinsky, Katia ^a,b,c   Doly, Stéphane ^a,b,c   Maroteaux, Luc ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSTITUT DU FER À MOULIN   (France)

^d Facultad de Medicina   (Argentina)

Author keywords

5 HT2B; Chronic stress; Depression; Receptor; Serotonin; SSRI antidepressants

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DESIPRAMINE; FLUOXETINE; NEUROTROPHIC FACTOR; PROTEIN P75; SEROTONIN 2B RECEPTOR; SUCROSE; ANTIDEPRESSANT AGENT; PROTEIN BINDING; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CHRONIC STRESS; CONTROLLED STUDY; DRUG EXPOSURE; GENE; HIPPOCAMPUS; LONG TERM EXPOSURE; MALE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; PHENOTYPE; PRIORITY JOURNAL; SOCIAL ASPECT; TREATMENT RESPONSE; ANIMAL; CELL PROLIFERATION; DEFICIENCY; DEPRESSIVE DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; FEEDING BEHAVIOR; GENETICS; LOCOMOTION; MAZE TEST; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGY; REACTION TIME; SWIMMING; TRANSGENIC MOUSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL PROLIFERATION; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEEDING BEHAVIOR; HIPPOCAMPUS; LOCOMOTION; MALE; MAZE LEARNING; MICE; MICE, TRANSGENIC; PROTEIN BINDING; REACTION TIME; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SWIMMING;

EID: 84958176822     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.12.012     Document Type: Article

References (47)

1. Bally-Cuif L., Wassef M. Ectopic induction and reorganization of Wnt-expression in quail/chick chimeras. Development 1994, 120:3379-3394.
2. Banas S.M., Diaz S.L., Doly S., Belmer A., Maroteaux L. Commentary: chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift. Front. Behav. Neurosci. 2015, 9:1-3.
3. Bechtholt A.J., Smith K., Gaughan S., Lucki I. Sucrose intake and fasting glucose levels in 5-HT(1A) and 5-HT(1B) receptor mutant mice. Physiol. Behav. 2008, 93:659-665.
4. Bevilacqua L., Doly S., Kaprio J., Yuan Q., Tikkanen R., Paunio T., Zhou Z., Wedenoja J., Maroteaux L., Diaz S., Belmer A., Hodgkinson C., Dell'Osso L., Suvisaari J., Coccaro E., Rose R., Peltonen L., Virkkunen M., Goldman D. A population-specific HTR2B stop codon predisposes to severe impulsivity. Nature 2010, 468:1061-1066.
5. Blazer D.G., Hybels C.F. Origins of depression in later life. Psychol. Med. 2005, 35:1241-1252.
6. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat. Rev. Drug Discov. 2005, 4:775-790.
7. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23:238-245.
8. Cryan J.F., Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol. Psychiatry 2004, 9:326-357.
9. Deltheil T., Guiard B.P., Cerdan J., David D.J., Tanaka K.F., Reperant C., Guilloux J.P., Coudore F., Hen R., Gardier A.M. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology 2008, 55:1006-1014.
10. Diaz S.L., Doly S., Narboux-Nême N., Fernandez S., Mazot P., Banas S., Boutourlinsky K., Moutkine I., Belmer A., Roumier A., Maroteaux L. 5-HT2B receptors are required for serotonin-selective antidepressant actions. Mol. Psychiatry 2012, 17:154-163.
11. Diaz S.L., Maroteaux L. Implication of 5-HT2B receptors in the serotonin syndrome. Neuropharmacology 2011, 61:495-502.
12. Diaz S.L., Maroteaux L. Dissecting a model of depressive-related phenotype and antidepressants effects in 129S2/SvPas mice. Serotonin Receptor Technologies, Neuromethods 2015, vol. 95:59-82. Springer, New York.
13. Doly S., Valjent E., Setola V., Callebert J., Herve D., Launay J.M., Maroteaux L. Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J. Neurosci. 2008, 28:2933-2940.
14. Ducottet C., Aubert A., Belzung C. Susceptibility to subchronic unpredictable stress is related to individual reactivity to threat stimuli in mice. Behav. Brain Res. 2004, 155:291-299.
15. Dulawa S.C., Hen R. Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci. Biobehav. Rev. 2005, 29:771-783.
16. Fanselow M.S., Dong H.-W. Are the dorsal and ventral hippocampus functionally distinct structures?. Neuron 2010, 65:7-19.
17. Galeotti N., Ghelardini C. Antidepressant phenotype by inhibiting the phospholipase Cbeta(1)--protein kinase Cgamma pathway in the forced swim test. Neuropharmacology 2011, 60:937-943.
18. Griebel G., Simiand J., Serradeil-Le Gal C., Wagnon J., Pascal M., Scatton B., Maffrand J.P., Soubrie P. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. USA 2002, 99:6370-6375.
19. Hertz L., Rothman D.L., Li B., Peng L. Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift. Front. Behav. Neurosci. 2015, 9:25.
20. Ibarguen-Vargas Y., Surget A., Touma C., Palme R., Belzung C. Multifaceted strain-specific effects in a mouse model of depression and of antidepressant reversal. Psychoneuroendocrinology 2008, 33:1357-1368.
21. Ibarguen-Vargas Y., Surget A., Vourc'h P., Leman S., Andres C.R., Gardier A.M., Belzung C. Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav. Brain Res. 2009, 202:245-251.
22. Kolodziejczak M., Bechade C., Gervasi N., Irinopoulou T., Banas S.M., Cordier C., Rebsam A., Roumier A., Maroteaux L. Serotonin modulates developmental microglia via 5-HT2B receptors: potential implication during synaptic refinement of retinogeniculate projections. ACS Chem. Neurosci. 2015, 6:1219-1230.
23. Krabbe G., Matyash V., Pannasch U., Mamer L., Boddeke H.W.G.M., Kettenmann H. Activation of serotonin receptors promotes microglial injury-induced motility but attenuates phagocytic activity. Brain Behav. Immun. 2012, 26:419-428.
24. Kupfer D.J., Frank E., Phillips M.L. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012, 379:1045-1055.
25. Larsen M.H., Mikkelsen J.D., Hay-Schmidt A., Sandi C. Regulation of brain-derived neurotrophic factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. J. Psychiatr. Res. 2010, 44:808-816.
26. Lee S., Jeong J., Kwak Y., Park S.K. Depression research: where are we now?. Mol. Brain 2010, 3:8.
27. Lucki I., Dalvi A., Mayorga A.J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 2001, 155:315-322.
28. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000, 20:9104-9110.
29. Mombereau C., Kawahara Y., Gundersen B.B., Nishikura K., Blendy J.A. Functional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors. Neuropharmacology 2010, 59:468-473.
30. Monteggia L.M., Barrot M., Powell C.M., Berton O., Galanis V., Gemelli T., Meuth S., Nagy A., Greene R.W., Nestler E.J. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl. Acad. Sci. USA 2004, 101:10827-10832.
31. Navarro J.F., Maldonado E. Acute and subchronic effects of MDMA ("ecstasy") on anxiety in male mice tested in the elevated plus-maze. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:1151-1154.
32. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 1995, 15:7539-7547.
33. O'Leary O.F., Cryan J.F. A ventral view on antidepressant action: roles for adult hippocampal neurogenesis along the dorsoventral axis. Trends Pharmacol. Sci. 2014, 35:675-687.
34. Petrik D., Lagace D.C., Eisch A.J. The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building?. Neuropharmacology 2012, 62:21-34.
35. Quesseveur G., Gardier A.M., Guiard B.P. The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs. Curr. Drug Targets 2013, 14:1277-1294.
36. Russo-Neustadt A.A., Alejandre H., Garcia C., Ivy A.S., Chen M.J. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology 2004, 29:2189-2199.
37. Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., Agerman K., Haapasalo A., Nawa H., Aloyz R., Ernfors P., Castren E. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 2003, 23:349-357.
38. Sairanen M., Lucas G., Ernfors P., Castrén M., Castrén E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J. Neurosci. 2005, 25:1089-1094.
39. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
40. Sclafani A. Sucrose motivation in sweet "sensitive" (C57BL/6J) and "subsensitive" (129P3/J) mice measured by progressive ratio licking. Physiol. Behav. 2006, 87:734-744.
41. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 2002, 22:3251-3261.
42. Siuciak J.A., Lewis D.R., Wiegand S.J., Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 1997, 56:131-137.
43. Southwick S.M., Charney D.S. The science of resilience: implications for the prevention and treatment of depression. Science 2012, 338:79-82.
44. Thomas L., Kessler D., Campbell J., Morrison J., Peters T.J., Williams C., Lewis G., Wiles N. Prevalence of treatment-resistant depression in primary care: cross-sectional data. Br. J. Gen. Pract. 2013, 63:e852-e858.
45. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 2006, 9:519-525.
46. Willner P., Muscat R., Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci. Biobehav. Rev. 1992, 16:525-534.
47. Yalcin I., Belzung C., Surget A. Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey. Behav. Brain Res. 2008, 193:140-143.